The estimated Net Worth of Pierre Beaurang is at least $281 Tausend dollars as of 10 August 2021. Pierre Beaurang owns over 7,500 units of Nurix Therapeutics stock worth over $281,199 and over the last 4 years Pierre sold NRIX stock worth over $0.
Sign up
Pierre Beaurang NRIX stock SEC Form 4 insiders trading
Pierre has made over 8 trades of the Nurix Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Pierre exercised 7,500 units of NRIX stock worth $8,325 on 10 August 2021.
The largest trade Pierre's ever made was exercising 15,000 units of Nurix Therapeutics stock on 18 February 2021 worth over $55,200. On average, Pierre trades about 7,148 units every 19 days since 2021. As of 10 August 2021 Pierre still owns at least 11,830 units of Nurix Therapeutics stock.
You can see the complete history of Pierre Beaurang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pierre Beaurang's mailing address?
Pierre's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Insiders trading at Nurix Therapeutics
Over the last 4 years, insiders at Nurix Therapeutics have traded over $1,236,800 worth of Nurix Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall und Biomedical Innovation Maste.... On average, Nurix Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $116,806. The most recent stock trade was executed by Christine Ring on 3 September 2024, trading 9,050 units of NRIX stock currently worth $42,173.
What does Nurix Therapeutics do?
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
What does Nurix Therapeutics's logo look like?
Complete history of Pierre Beaurang stock trades at Nurix Therapeutics
Nurix Therapeutics executives and stock owners
Nurix Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Arthur T. Sands M.D., Ph.D.,
CEO, Pres & Director -
Dr. Arthur T. Sands,
CEO, Pres & Director -
Dr. Gwenn M. Hansen Ph.D.,
Chief Scientific Officer -
Dr. Christine Ring,
Gen. Counsel & Sec. -
Stefani A. Wolff,
COO & Exec. VP of Product Devel. -
Dr. Michael Rapé Ph.D.,
Founder & Member of Scientific Advisory Board -
Rita Kwong,
Sr. Accounting Mang. -
Howard A. Simon J.D., Esq., SPHR,
VP of Operations & Corp. Counsel -
Johannes Van Houte,
Chief Financial Officer -
Prof. Arthur Weiss,
Founder & Member of Scientific Advisory Board -
Dr. Michael Rapé Ph.D.,
Founder & Member of Scientific Advisory Board -
Dr. John Kuriyan,
Founder & Member of Scientific Advisory Board -
Rock Ventures Iii, L.P.Thir...,
-
Gwenn Hansen,
Chief Scientific Officer -
Leon Chen,
Director -
Lori Anne Kunkel,
Director -
David L. Lacey,
Director -
Julia P Gregory,
Director -
Jeffrey K Tong,
Director -
Group L Pcolumn Group Gp, L...,
-
Group L P Svennilson Peter ...,
-
Robert Tjian,
Director -
Group, Llc Green Jeremy Red...,
-
Biomedical Innovation Maste...,
10% owner -
Arthur T Sands,
President, CEO -
Stefani Wolff,
EVP and COO -
Rock Ventures Iii, L.P.Thir...,
-
Houte Hans Van,
Chief Financial Officer -
Pierre Beaurang,
Chief Business Officer -
Clay B Siegall,
Director -
Paul M Silva,
Director -
Judith A Reinsdorf,
Director -
Edward C Saltzman,
Director -
Christine Ring,
Chief Legal Officer